FR3130161A3 - Réparation complète des dommages liés a la lumière - Google Patents

Réparation complète des dommages liés a la lumière Download PDF

Info

Publication number
FR3130161A3
FR3130161A3 FR2113318A FR2113318A FR3130161A3 FR 3130161 A3 FR3130161 A3 FR 3130161A3 FR 2113318 A FR2113318 A FR 2113318A FR 2113318 A FR2113318 A FR 2113318A FR 3130161 A3 FR3130161 A3 FR 3130161A3
Authority
FR
France
Prior art keywords
composition
extract
composition according
damage
plankton
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR2113318A
Other languages
English (en)
Other versions
FR3130161B3 (fr
Inventor
Olivier Doucet
Cécile CHAMAYOU-ROBERT
Muriel Pujos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coty Inc
Original Assignee
Coty Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coty Inc filed Critical Coty Inc
Priority to FR2113318A priority Critical patent/FR3130161B3/fr
Priority to PCT/US2022/081185 priority patent/WO2023108072A1/fr
Priority to EP22847082.9A priority patent/EP4444328A1/fr
Priority to NL2033692A priority patent/NL2033692B1/en
Priority to CN202280079619.9A priority patent/CN118354778A/zh
Priority to US18/694,262 priority patent/US20240398885A1/en
Publication of FR3130161A3 publication Critical patent/FR3130161A3/fr
Application granted granted Critical
Publication of FR3130161B3 publication Critical patent/FR3130161B3/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/02—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2)
    • C12Y302/02017—Deoxyribodipyrimidine endonucleosidase (3.2.2.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/99—Other Carbon-Carbon Lyases (1.4.99)
    • C12Y401/99003—Deoxyribodipyrimidine photo-lyase (4.1.99.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/99—Other carbon-oxygen lyases (4.2.99)
    • C12Y402/99018—DNA-(apurinic or apyrimidinic site)lyase (4.2.99.18)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/592—Mixtures of compounds complementing their respective functions
    • A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Marine Sciences & Fisheries (AREA)

Abstract

[La présente invention concerne un procédé de traitement de dommages cutanés dus à la lumière, comprenant l’administration topique à un sujet qui en éprouve le besoin d’une composition comprenant une quantité suffisante d’extrait d’Arabidopsis thaliana, de lysat de Micrococcus et d’extrait de plancton pour traiter simultanément les dommages causés par l’exposition de la peau aux UVA, aux UVB, à la lumière infrarouge, à la lumière visible ou une combinaison de ceux-ci. Figure à publier avec l’abrégé : Fig. 1]

Description

RÉPARATION COMPLÈTE DES DOMMAGES LIÉS A LA LUMIÈRE
Contexte
[La peau humaine est constamment exposée à la lumière du soleil. Le rayonnement solaire atteignant la surface terrestre comprend un rayonnement ultraviolet (UV) (290 à 400 nm), de la lumière visible (400 à 760 nm) et un rayonnement infrarouge (IR) (760 nm à 1 mm). Chacune de ces longueurs d’onde génère des dommages de l’ADN spécifiques, tels que des dommages oxydatifs (comme la 8-oxoguanine) et des dimères cyclobutyliques de pyrimidine (CPD). Les dommages de l’ADN contribuent au vieillissement prématuré de la peau.
Résumé
L’invention concerne des compositions et des procédés de réparation de dommages de l’ADN induits par les UVB, les UVA, la lumière visible, notamment la lumière bleue et l’infrarouge. On sait aujourd’hui que l’application, notamment topique, d’extrait d’Arabidopsis thaliana, de lysat de Micrococcus et d’extrait de plancton seuls et/ou en combinaison permet de minimiser et/ou de prévenir, y compris d’inverser, les micro- et macro-manifestations moléculaires du vieillissement cutané, notamment le vieillissement cutané dû à la lumière UV, VIS, IR, et/ou les photodommages.
Brève description des figures
La présente un graphique représentant la capacité des compositions divulguées ici à améliorer la réparation de l’ADN de dommages oxydatifs de l’ADN et de dommages CPD induits par des rayonnements solaires (amélioration de la réparation de l’ADN). Il inclut des longueurs d’onde dans l’UV, la lumière bleue en tant que partie de la lumière visible et l’infrarouge.
La présente un graphique représentant la capacité des compositions divulguées ici à améliorer la réparation de l’ADN de dommages oxydatifs de l’ADN et de dommages CPD induits par les rayonnements solaires (augmentation du taux de réparation de l’ADN). Il inclut des longueurs d’onde dans l’UV, la lumière bleue en tant que partie de la lumière visible et l’infrarouge.

Claims (14)

  1. Composition comprenant une quantité suffisante d’extrait d’Arabidopsis thaliana, de lysat de Micrococcus et d’extrait de plancton pour utilisation pour traiter simultanément les dommages causés par l’exposition de la peau aux UVA, aux UVB, à la lumière infrarouge, à la lumière visible ou une combinaison de ceux-ci.
  2. Composition comprenant une quantité suffisante d’extrait d’Arabidopsis thaliana, de lysat de Micrococcus et d’extrait de plancton pour utilisation pour de réparer simultanément des dommages de l’ADN dans des cellules cutanées causés par l’exposition de la peau à la lumière visible, aux UVB, aux UVA, à la lumière visible et/ou infrarouge, dans laquelle la composition est appliquée topiquement sur des cellules cutanées.
  3. Composition comprenant une quantité suffisante d’extrait d’Arabidopsis thaliana, de lysat de Micrococcus et d’extrait de plancton pour utilisation pour réduire le vieillissement prématuré de la peau, dans laquelle la composition est appliquée topiquement sur des cellules cutanées.
  4. Composition selon l’une quelconque des revendications 1 à 3, dans laquelle les dommages de l’ADN sont dus à une exposition à la lumière bleue, dans laquelle les dommages de l’ADN sont des dommages oxydatifs de l’ADN et/ou des dommages de l’ADN de type dimères cyclobutaniques de pyrimidine (CPD), dans laquelle les dommages par lumière bleue sont détectés par un test des comètes à l’aide de formamidopyrimidine DNA glycosylase (FPG) ou d’endonucléase T4 V afin de détecter des bases d’ADN oxydées et des dimères cyclobutaniques de pyrimidine (CPD), respectivement.
  5. Composition selon l’une quelconque des revendications 1 à 4, dans laquelle la composition comprend en outre de la créatine.
  6. Composition selon l’une quelconque des revendications 1 à 5, dans laquelle la composition comprend environ 0,00005 % à 0,002 % (p/p) d’extrait d’Arabidopsis thaliana.
  7. Composition selon l’une quelconque des revendications 1 à 6, dans laquelle la composition comprend environ 0,00005 % à 0,02 % (p/p) de lysat de Micrococcus.
  8. Composition selon l’une quelconque des revendications 1 à 7, dans laquelle la composition comprend environ 0,00005 % à 0,02 % (p/p) d’extrait de plancton.
  9. Composition selon l’une quelconque des revendications 1 à 8, dans laquelle les dommages de l’ADN sont des dimères cyclobutaniques de pyrimidine (CPD) et/ou des lésions oxydatives.
  10. Composition selon l’une quelconque des revendications 1 à 9, dans laquelle l’extrait d’Arabidopsiscomprend de l’oxo-guanine glycosylase-1 (OGG1), le lysat de Micrococcus comprend de l’UV-endonucléase et l’extrait de plancton comprend de la photolyase.
  11. Composition selon l’une quelconque des revendications 1 à 10, dans laquelle la composition comprend en outre un liposome.
  12. Composition selon la revendication 11, dans laquelle le liposome est la lécithine.
  13. Composition selon la revendication 11, dans laquelle le liposome comprend de la phosphatidyléthanolamine, de la phosphatidylcholine, de l’hémisuccinate de cholestéryle ou une combinaison de ceux-ci.
  14. Composition comprenant de l’extrait de plancton (photolyase), de l’extrait d’Arabidopsis thaliana(oxo-guanine glycosylase-1 (OGG-1)) et du lysat de Micrococcus (UV-endonucléase).]
FR2113318A 2021-12-10 2021-12-10 Réparation complète des dommages liés a la lumière Active FR3130161B3 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR2113318A FR3130161B3 (fr) 2021-12-10 2021-12-10 Réparation complète des dommages liés a la lumière
PCT/US2022/081185 WO2023108072A1 (fr) 2021-12-10 2022-12-08 Réparation de lumière totale
EP22847082.9A EP4444328A1 (fr) 2021-12-10 2022-12-08 Réparation de lumière totale
NL2033692A NL2033692B1 (en) 2021-12-10 2022-12-08 Full light repair
CN202280079619.9A CN118354778A (zh) 2021-12-10 2022-12-08 全光修复
US18/694,262 US20240398885A1 (en) 2021-12-10 2022-12-08 Full light repair

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2113318A FR3130161B3 (fr) 2021-12-10 2021-12-10 Réparation complète des dommages liés a la lumière
FR2113318 2021-12-10

Publications (2)

Publication Number Publication Date
FR3130161A3 true FR3130161A3 (fr) 2023-06-16
FR3130161B3 FR3130161B3 (fr) 2024-03-29

Family

ID=81326148

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2113318A Active FR3130161B3 (fr) 2021-12-10 2021-12-10 Réparation complète des dommages liés a la lumière

Country Status (6)

Country Link
US (1) US20240398885A1 (fr)
EP (1) EP4444328A1 (fr)
CN (1) CN118354778A (fr)
FR (1) FR3130161B3 (fr)
NL (1) NL2033692B1 (fr)
WO (1) WO2023108072A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800197A (en) 1987-07-17 1989-01-24 Richardson-Vicks Inc. Anti-acne composition
US4835148A (en) 1986-02-24 1989-05-30 The Procter & Gamble Co. Shampoo compositions comprising water-insoluble particulate anti-inflammatory agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110305737A1 (en) * 2010-06-09 2011-12-15 NY Derm LLC Multi-Active Microtargeted Anti-Aging Skin Cream Polymer Technology
US9333159B2 (en) * 2011-04-29 2016-05-10 Photomedex, Inc. Topical DNA repair composition
WO2014093645A2 (fr) * 2012-12-13 2014-06-19 Precision Dermatology, Inc. Formulations topiques pour augmenter la concentration dermique d'acide hyaluronique
RU2637636C1 (ru) * 2013-11-26 2017-12-05 Дэрмопартнерс, С.Л. Косметический продукт со свойствами репарации днк клеток кожи

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4835148A (en) 1986-02-24 1989-05-30 The Procter & Gamble Co. Shampoo compositions comprising water-insoluble particulate anti-inflammatory agents
US4800197A (en) 1987-07-17 1989-01-24 Richardson-Vicks Inc. Anti-acne composition

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Application of Emulsion Stability Theories to Mobile and Semisolid Oil-in-Water Emulsions", COSMETICS AND TOILETRIES, vol. 101, November 1986 (1986-11-01)
"Mc-Cutcheon's Detergents and Emulsifiers", 1986, ALLURED PUBLISHING CORPORATION
"Personal Care Product Council's International Cosmetic Ingrédient Dictionary and Handbook", 2010, article "Sunscreen Agents"
AZQUETA ET AL., MUTAGENESIS, vol. 28, 2013, pages 271 - 277
CHAMAYOU-ROBERT ET AL., PHO-TODERMATOL. PHOTOIMMUNOL. PHOTOMED., vol. 00, 2021, pages 1 - 7
JEAN ET AL., PHOTOCHEM PHOTOBIOL., vol. 74, no. 3, 2007
PHOTODERM PHOTOIMMUN., vol. 00, 2021, pages 1 - 7
SAGARIN, COSMETICS SCIENCE AND TECHNOLOGY, vol. 2, 1972
SAGARIN, COSMETICS, SCIENCE AND TECHNOLOGY, vol. l, 1972
WISCHERMANN ET AL., MUTAT RES, vol. 630, 2007, pages 122 - 128

Also Published As

Publication number Publication date
EP4444328A1 (fr) 2024-10-16
NL2033692A (en) 2023-06-26
FR3130161B3 (fr) 2024-03-29
NL2033692B1 (en) 2023-12-21
US20240398885A1 (en) 2024-12-05
CN118354778A (zh) 2024-07-16
WO2023108072A1 (fr) 2023-06-15

Similar Documents

Publication Publication Date Title
Dare et al. Abilities of protocatechuic acid and its alkyl esters, ethyl and heptyl protocatechuates, to counteract UVB-induced oxidative injuries and photoaging in fibroblasts L929 cell line
Espín et al. Effect of captopril on mushroom tyrosinase activity in vitro
Liu et al. Modification of arginines in trypsin inhibitors by 1, 2-cyclohexanedione
Fitt et al. Response of two species of Indo-Pacific corals, Porites cylindrica and Stylophora pistillata, to short-term thermal stress: The host does matter in determining the tolerance of corals to bleaching
Comim et al. Mitochondrial respiratory chain and creatine kinase activities in rat brain after sepsis induced by cecal ligation and perforation
Mansouri et al. Alterations in mitochondrial function, hydrogen peroxide release and oxidative damage in mouse hind-limb skeletal muscle during aging
Jin et al. Apigenin protects endothelium-dependent relaxation of rat aorta against oxidative stress
FR2832637A1 (fr) Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface
Dawson et al. A hydrogen peroxide safety valve: The reversible phosphorylation of catalase from the freeze-tolerant North American wood frog, Rana sylvatica
FR3130161A3 (fr) Réparation complète des dommages liés a la lumière
Jayalakshmi et al. Cardioprotective effect of tincture of Crataegus on isoproterenol-induced myocardial infarction in rats
RU2493834C2 (ru) Смягчающая композиция
Cruz-Álvarez et al. Apocynin protects against neurological damage induced by quinolinic acid by an increase in glutathione synthesis and Nrf2 levels
CO2024001711A2 (es) Anticuerpos anti hla-g
Choi et al. Component analysis of sweet BV and clinical trial on antibody titer and allergic reactions
FR2746008A1 (fr) Composition a usage topique anti-vieillissement
Kováčik et al. Oxidative stress, uptake and bioconversion of 5-fluorouracil in algae
FR3022139A1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
US20150132366A1 (en) Compositions for Preventing and Repairing Skin and Ocular Damages Caused by UV Radiations
JP6391837B2 (ja) Ｓｉｒｔ６活性化剤及びＤＮＡ修復酵素を含有する組成物
Barone et al. Effects of N-acetyl-L-cysteine on redox status and markers of renal function in mice inoculated with Bothrops jararaca and Crotalus durissus terrificus venoms
FR3080520B1 (fr) Composition phytosanitaire a base d'huiles essentielles, utilisation et procede de traitement d'une plante
EP0954280A1 (fr) Utilisation d'un extrait de terminalia catappa
FR3010904A1 (fr) Bacteries du genre stenotrophomonas et/ou inducteur de croissance desdites bacteries pour la prevention et/ou le traitement de la dermatite atopique
WO1998037863A2 (fr) Proprietes et synergies entre elles et avec des extraits naturels et/ou substances d'origine naturelle, des extraits et huiles des plantes du genre calophyllum, bertholletia et moringa, applications endietetique, cosmetique et therapie

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5